Luminex Corporation (NASDAQ:LMNX) Ratings Summary as of Jun 29, 2018

June 29, 2018 - By Loretta Love

Luminex Corporation (NASDAQ:LMNX) Corporate Logo

Luminex Corporation (NASDAQ:LMNX) Ratings Coverage

In total 2 analysts cover Luminex (NASDAQ:LMNX). “Buy” rating has 1, “Sell” are 0, while 1 are “Hold”. (NASDAQ:LMNX) has 50% bullish analysts. 3 are the (NASDAQ:LMNX)’s ratings reports on Jun 29, 2018 according to StockzIntelligence Inc. On Monday, May 7 the rating was upgraded by Deutsche Bank to “Hold”. Listed here are Luminex Corporation (NASDAQ:LMNX) PTs and latest ratings.

07/05/2018 Broker: Deutsche Bank Rating: Hold New Target: $22.0000 Upgrade
08/01/2018 Broker: BTIG Research Rating: Buy New Target: $24.0
05/01/2018 Broker: BTIG Research Rating: Buy New Target: $24 Initiates Coverage On

The stock increased 1.14% or $0.33 during the last trading session, hitting $29.21.Currently Luminex Corporation is uptrending after 33.74% change in last June 29, 2017. LMNX has 53,454 shares volume. LMNX outperformed the S&P500 by 21.17%.

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and life sciences industries worldwide.The company has $1.30 billion market cap. The companyÂ’s products include Luminex LX 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; Verigene system, an automated multiplex-capable system; and ARIES system, a sample to answer real-time PCR platform.The P/E ratio is 38.38. It also offers MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; ARIES cassettes that are self-contained assay consumables; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; respiratory viral family of products to identify the causative agent for respiratory infections; and gastrointestinal pathogen panel assays to identify the pathogens causing infectious gastroenteritis.

More recent Luminex Corporation (NASDAQ:LMNX) news were posted by Streetinsider.com, Globenewswire.com and Prnewswire.com. The first one has “Luminex Corp. (LMNX) Initiates Clinical Trials for VERIGENE II Gastrointestinal Assay” as a title and was posted on June 13, 2018. The next is “Detailed Research: Economic Perspectives on MGM Growth Properties, Acacia Research, Luminex, Eastman …” on June 20, 2018. And last was posted on June 13, 2018, called “Luminex Initiates Clinical Trials for VERIGENE® II Gastrointestinal Assay”.

Luminex Corporation (NASDAQ:LMNX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: